Was that analysis really and truly prespecified? It’s not listed as one of the myriad secondary endpoints in the REDUCE-IT listing on ct.gov (https://www.clinicaltrials.gov/ct2/show/NCT01492361 ). It's listed as a tertiary end point in the protocol, which is available in the New England Journal. It does not say how the analysis was performed.